IMMUNITYBIO INC (IBRX)
NASDAQ • Healthcare
$7.72
-$0.2 (-2.5%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About IMMUNITYBIO INC
Name
IMMUNITYBIO INC
CEO
Richard Gerald Adcock
Website
Industry
Healthcare
Year Founded
2014
Employees
688
ImmunityBio, Inc. (NASDAQ: IBRX) is a biotechnology company that develops therapies and vaccines for cancer and infectious disease using immunotherapy and cell therapy platforms. In FY2025, it generated $113.3 million in revenue. Its programs span antibody-cytokine fusion proteins, immunomodulators, vaccine technologies, NK cell therapies, and T-cell strategies.
Fundamentals & Financials
Revenue (TTM)
$165.7M
Net Income (TTM)
-$992.3M
EPS (TTM)
-$0.97
ROA (TTM)
-157.89%
Current Ratio
5.72
Dividend Yield
0%
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$7.72$7.54 - $7.83
52 Week RangeAvg. Volume$1.95 - $12.438.5M
Market Cap$8.4B
Peers & Related Assets
LQDALIQUIDIA CORP
$74.33-4.3%
COGTCOGENT BIOSCIENCES INC
$37.4-1.2%
DNLIDENALI THERAPEUTICS INC
$24.31-0.2%
RCUSARCUS BIOSCIENCES INC
$29.51-0.2%
BEAMBEAM THERAPEUTICS INC
$26.57-2.0%
VRDNVIRIDIAN THERAPEUTICS ORS INC
ETNB89bio, Inc.
AGIOAGIOS PHARMACEUTICALS INC
GLPGGalapagos N.V.
RXRXRECURSION PHARMACEUTICALS INC CLAS